

.Cairo University
Faculty of Veterinary Medicine
Department of Pharmacology

**Effect of prebiotic on disposition and tissue residues of
tylvalosin in apparently healthy and *Mycoplasma*
gallisepticum infected broiler chickens**

Thesis presented by

Ammar Haki Salman
(M.V.Sc. Baghdad University, 1997)

For
The Degree of Ph.D.
(Veterinary Pharmacology)

Under Supervision of

Prof. Dr. Amer Ramadan Ali Ayad
Professor and Head of Pharmacology Department
Faculty of Veterinary Medicine
Cairo University

Prof. Dr. Salah El-Din Abdel Hamid Mohamed Youssef
Professor of Pharmacology
Faculty of Veterinary Medicine
Cairo University

Dr. Ahmed Mohamed Galal Mohamed
Assistant Prof. of Pharmacology
Faculty of Veterinary Medicine
Cairo University
(2017)

Supervisors

Prof. Dr. Amer Ramadan Ali Ayad

Professor and Head of Pharmacology Department

Faculty of Veterinary Medicine

Cairo University

Prof. Dr. Salah El-Din Abdel Hamid Mohamed Youssef

Professor of Pharmacology

Faculty of Veterinary Medicine

Cairo University

Dr. Ahmed Mohamed Galal Mohamed

Assistant Prof. of Pharmacology

Faculty of Veterinary Medicine

Cairo University

Cairo University
Faculty of Veterinary Medicine
Department of Pharmacology
Name: Ammar Haki Salman

Degree: Ph.D.V.SC

Specification: Veterinary Pharmacology

Title: Effect of prebiotic on disposition and tissue residues of tylvalosin in apparently healthy and *Mycoplasma gallisepticum* infected broiler chickens
Supervision:

1- Prof. Dr. Amer Ramadan Ali Ayad.

2- Prof. Dr. Salah El-Din Abdel Hamid Mohamed Youssef.

3-Dr. Ahmed Mohamed Galal Mohamed.

Abstract

A study of tylvalosin pharmacokinetics was conducted in healthy, health pretreated with prebiotic, *Mycoplasma gallisepticum*-infected and *Mycoplasma gallisepticum*-infected pretreated with prebiotic broiler chickens. Tylvalosin was administered intravenously and orally as a single dose of (25 mg/kg b.wt.) to determine its concentrations in blood as well as its kinetic disposition, the oral dose was repeated for 5 consecutive days to determine the tissues residues.

The serum concentration - time curve indicated a two-compartment open model. Following intravenous injection, the mean elimination half-lives ($t_{1/2\beta}$) of (6.666 ± 0.285 , 6.501 ± 1.143 , 3.048 ± 0.232 and 4.284 ± 0.204 h) The apparent volume of distribution ($V_{d(\text{area})}$) of tylvalosin was (3.802 ± 0.148 , 6.362 ± 0.390 , 0.657 ± 0.367 and 6.080 ± 2.928 L/Kg) with body clearance CL_{β} (0.953 ± 0.040 , 1.792 ± 0.062 , 1.976 ± 0.743 and 3.592 ± 0.532 L/kg/h) with mean of MRT was (9.314 ± 0.407 , 7.533 ± 0.735 , 1.739 ± 0.779 and 4.853 ± 0.388 h) in four groups, respectively. Following oral administration, tylvalosin was absorbed with ($t_{1/2\alpha}$) of (0.963 ± 0.045 , 0.906 ± 0.025 , 0.958 ± 0.207 and 0.956 ± 0.030 h) with peak serum concentration (C_{max}) of (1.226 ± 0.024 , 0.873 ± 0.009 , 0.0760 ± 0.024 and 0.854 ± 0.020 $\mu\text{g/ml}$) at (t_{max}) of (1.723 ± 0.041 , 1.441 ± 0.023 , 1.310 ± 0.055 and 1.472 ± 0.025 h) and eliminated with ($t_{1/2\beta}$) of (3.504 ± 0.049 , 3.600 ± 0.165 , 3.862 ± 0.103 and 3.132 ± 0.114 h) in four groups, respectively. The systemic bioavailability of Tylvalosin (F%) following oral administration was (47.491 ± 0.538 , 52.853 ± 0.416 , 72.96 ± 0.003 and 88.652 ± 6.714 %) in four groups, respectively.

After single intravenous and oral dose the highest level of drug was concentrated in lung tissue comparable with other tissues, and after repeated oral doses the drug was still detected in lung tissue after 196 hour of the last dose while it is not detected in other tissues.

It is to conclude that serum and tissues tylvalosin concentration following twice-daily dose of (25 mg/Kg b. wt./day) were suitable to maintain its therapeutic regimen for treatment of mycoplasma infection in broiler chickens, in addition mycoplasma infection and prebiotic significantly decrease and/or consumed serum concentration, increased elimination rate so it is recommended that dose rate is adjusted in case of mycoplasma infection. Furthermore, tylvalosin should be withdrawn at least 8- 10 days, before marketing to ensure that the drug is completely eliminated from tissues.

*Oh, Allah, this matter began from you, continued by you
and its end is upon you, so I beg you to accept it from me,
you are the most forgiving, the most merciful*

ACKNOWLEDGEMENT

First of all, I administer the prayful thanks to (ALLAH) for his mercy and genericity, for his aids and for helping me to carry out and end of this work,

I wish to express my sincere gratitude, grateful thanks and deep appreciation to Prof. Dr. Amer Ramadan Ali Ayad, Professor and Head of Pharmacology Department, Faculty of Veterinary Medicine, Cairo University for his close supervision to the work, valuable guidance and kindly offering his experience and time for completion this work,

My sincere thanks and very deep gratitude and appreciation to Prof. Dr. Salah El-Din Abdel Hamid Mohamed Youssef, Professor of Pharmacology, Faculty of Veterinary Medicine, Cairo University, for his kind supervision, encouragement in many times when problems occur, for his advices in hard times and for his close careful to me and to the work,

Deep appreciation and grateful thanks to Dr. Ahmed Mohamed Galal Mohamed, assistant prof. of Pharmacology, Faculty of Veterinary Medicine, Cairo University, for his precious help, valuable advice and brotherhood behaviors with me.

My deep appreciation and thanks to anybody helped me in this work even by a word.

﴿أَلَا يَعْلَمُ مَنْ خَلَقَ وَهُوَ اللَّطِيفُ الْخَبِيرُ﴾ ﴿هُوَ
الَّذِي جَعَلَ لَكُمُ الْأَرْضَ ذُلُولًا فَامْشُوا فِي مَنَاكِبِهَا
وَكُلُوا مِنْ رِزْقِهِ وَإِلَيْهِ النُّشُورُ﴾

سورة الملك:

الآيات (14-15)

CONTENTS

1-Introduction	1
2-Review of literature	6
Macrolides	6
2-1-1-Mechanism of action	6
2-1-2-Pharmacokinetics	7
2-1-3-Macrolides uses	8
2-2-Tylvalosin	9
2-2-1-Pharmacokinetic and Residue	9
2-2-2-Indication and Uses	13
2-2-3-Toxicity and Side effects	19
2-3-Pharmacokinetic of other Macrolides	21
2-4-Prebiotics	36
2-4-1-Application of prebiotics in farm a	40
2-4-1-1-Poultry	40
2-4-1-2-Cattle	42
2-4-1-3-Pigs	43
3-Materials and Methods	
3-1-Materials	46
3-1-1-Drug	46
3-1-2-Prebiotic	47
3-1-3- <i>Mycoplasma gallisepticum</i>	47
3-1-4-Preparation of microbial suspension	47
3-1-5-Culture media	47
3-1-6-Assay of medium preparation of plates	48
3-1-7-Preparation of Phosphate Buffer	48
3-1-8-Chemicals	48
3-1-9-HPLC	49
3-2-Method	49
3-2-1-Preparation of the drug stock solution	49
3-2-2-Preparation of standard concentrations	49
3-2-3-Determination of protein binding of the drug in serum	50
3-2-4- Preparation of tissues standard	51
3-2-5- Preparation of tissues standard curve	51
3-3-Broiler chickens and experimental design	52
3-3-1-Blood and tissues samples	53
3-3-2-Blood samples assay	54

3-3-3-Tissues samples assay.....	54
3-4-Pharmacokinetic analysis.....	55
3-5-Statistical analysis.....	59
4-Results	
4-1-Intravenous injection of tylvalosin.....	65
4-1-1-Apparently healthy group.....	65
4-1-2-Healthy group pretreated with prebiotic.....	66
4-1-3- <i>M. gallisepticum</i> infected group.....	66
4-1-4- infected group pretreated with prebiotic.....	67
4-2-Single and repeated oral dose of tylvalosin.....	68
4-2-1- Apparently healthy group.....	68
4-2-2- Healthy group pretreated with prebiotic.....	69
4-2-3- <i>M. gallisepticum</i> infected group.....	70
4-2-4-infected group pretreated with prebiotic.....	71
4-3-Tissues residues studies.....	71
4-3-1-Single iv and oral dose.....	71
4-3-2-Repeated oral dose.....	73
4-4- <i>In vitro</i> Protein binding tendency.....	74
5-Discussion	
5-1-Tylvalosin pharmacokinetic.....	106
5-2- Tylvalosin tissues residues.....	113
6-Conclusion	115
Summary	116
References	121

LIST OF TABELS

N0.	Tables	Page
1	Tylvalosin concentration in serum ($\mu\text{g/ml}$) following intravenous injection (25mg/Kg b. wt) in healthy chickens not treated with prebiotic	83
2	Tylvalosin concentration in serum ($\mu\text{g/ml}$) following intravenous injection (25mg/Kg b.wt) in healthy chickens treated with prebiotic	83
3	Tylvalosin concentration in serum ($\mu\text{g/ml}$) following intravenous injection (25mg/Kg b.wt) in infected chickens not treated with prebiotic	84
4	Tylvalosin concentration in serum($\mu\text{g/ml}$) following intravenous injection (25mg/Kg b.wt) in infected chickens treated with prebiotic	84
5	Tylvalosin concentration in serum ($\mu\text{g/ml}$) following oral administration (25mg/Kg b.wt) in healthy chickens not treated with prebiotic	85
6	Tylvalosin concentration in serum ($\mu\text{g/ml}$) following oral administration (25mg/Kg b.wt) in healthy chickens treated with prebiotic	85
7	Tylvalosin concentration in serum ($\mu\text{g/ml}$) following oral administration (25mg/Kg b.wt) in infected chickens not treated with prebiotic	86
8	Tylvalosin concentration in serum($\mu\text{g/ml}$) following oral administration (25mg/Kg b.wt) in infected chickens treated with prebiotic	87
9	Tylvalosin pharmacokinetic parameters following intravenous injection (25mg/Kg b.wt) in healthy chickens not treated with prebiotic	88
10	Tylvalosin pharmacokinetic parameter in following intravenous injection (25mg/Kg b.wt) in healthy chickens treated with prebiotic	89
11	Tylvalosin pharmacokinetic parameter following intravenous injection (25mg/Kg b.wt) in infected chickens not treated with prebiotic	90